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The intracellular parasite Toxoplasma gondii can cause chronic infections in most
warm-blooded animals, including humans. In the USA, strains belonging to four different
Toxoplasma clonal lineages (types 1, 2, 3, and 12) are commonly isolated, whereas
strains not belonging to these lineages are predominant in other continents such as
South America. Strain type plays a pivotal role in determining the severity of Toxoplasma
infection. Therefore, it is epidemiologically relevant to develop a non-invasive and
inexpensive method for determining the strain type in Toxoplasma infections and to
correlate the genotype with disease outcome. Serological typing is based on the
fact that many host antibodies are raised against immunodominant parasite proteins
that are highly polymorphic between strains. However, current serological assays can
only reliably distinguish type 2 from non-type 2 infections. To improve these assays,
mouse, rabbit, and human infection serum were reacted against 950 peptides from
62 different polymorphic Toxoplasma proteins by using cellulose membrane peptide
arrays. This allowed us to identify the most antigenic peptides and to pinpoint the most
relevant polymorphisms that determine strain specificity. Our results confirm the utility of
previously described peptides and identify novel peptides that improve and increase the
specificity of the assay. In addition, a large number of novel proteins showed potential to
be used for Toxoplasma diagnosis. Among these, peptides derived from several rhoptry,
dense granule, and surface proteins represented promising candidates that may be used
in future experiments to improve Toxoplasma serotyping. Moreover, a redesigned version
of the published GRA7 typing peptide performed better and specifically distinguished
type 3 from non-type 3 infections in sera from mice, rabbits, and humans.
Keywords: Toxoplasma, serotyping, strain type, dense granule, peptide, microarrays
INTRODUCTION
Toxoplasma gondii is a ubiquitous obligate intracellular protozoan parasite that can infect virtually
all warm-blooded animals, including humans (Dabritz and Conrad, 2010). Although infection
is usually asymptomatic, it can also cause ocular toxoplasmosis (OT) in immunocompetent
individuals, encephalitis in immunocompromised individuals and abortion, birth defects or
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congenital OT in newborns from pregnant women infected for
the first time (Furtado et al., 2011). Indeed, the progression and
severity of toxoplasmosis depends on a combination of host
and parasite factors. The Toxoplasma strain type that causes
infection is one of the key factors known to influence the outcome
of the disease (Boothroyd and Grigg, 2002; Ajzenberg et al.,
2010; Fekkar et al., 2011). In the USA, strains belonging to
four different Toxoplasma clonal lineages (types 1, 2, 3, and
12) are commonly isolated from animals, whereas strains not
belonging to these lineages are predominant in other continents
such as South America (Herrmann et al., 2012; Su et al., 2012).
The latter are more virulent in mice compared to isolates
from North America, Europe, North Africa and Asia (Shwab
et al., 2016). Likewise, severe systemic toxoplasmosis resulting
in death of immune competent people infected with parasite
strains from South America have been reported (Carme et al.,
2009; Hamilton et al., 2019). By contrast, type 2 strains are
the most prevalent cause of human toxoplasmosis in Europe
and North America but are less often associated with the
most severe clinical cases. For example, in both congenital
infection and in immunosuppressed patients in the USA and
Europe, type 1 and other strains not common to these regions
are more likely to be found infecting immunocompetent
individuals suffering from severe, atypical OT (Grigg et al., 2002;
Shobab et al., 2013), or are disproportionately associated with
severe congenital toxoplasmosis (Howe et al., 1997; Fuentes
et al., 2001; Carme et al., 2002, 2009; McLeod et al., 2012;
Hutson et al., 2015). Nevertheless, caution is needed when
interpreting these reports, as most of these studies relied on
only a few molecular markers or alleles to identify the strain
type by PCR-restriction fragment length polymorphism (RFLP)
or microsatellite markers, and thus might be misclassified
(Lorenzi et al., 2016).
It is increasingly appreciated that if the strain genotype
causing infection is known, then treatment could be matched
to the specifics of the infection; for example patients infected
with virulent strains that have not yet developed OT could be
identified, and treatment options altered, such as more frequent
eye exams or prophylactic treatment to improve prognostic
outcomes (Arantes et al., 2015). A previous work showed that
OT patients infected with non-type 2 strains have a higher
chance of recurrent disease (Shobab et al., 2013), hence long-term
treatment could be recommended to patients infected with these
strains. Furthermore, once an association between Toxoplasma
strain and disease phenotype is established, experiments can
be designed to determine the molecular basis for the increased
virulence of the strain, which might ultimately lead to novel
therapies. It is therefore epidemiologically relevant to determine
the types dominating in particular regions and to investigate
if there are correlations between strain type and severity
of toxoplasmosis.
To enable large-scale investigations into the influence of
parasite genotype on the severity of disease, an assay that
identifies the strain infecting a patient is required. However,
the ability to genotype the infecting strain is often limited by
insufficient parasite DNA present in a patient’s sample (e.g.,
amniocentesis or vitreous fluid) (Lorenzi et al., 2016). Moreover,
parasites can only be obtained from symptomatic individuals in
very low amounts through difficult and risky biopsies. Hence,
what is needed is a rapid, highly sensitive, and non-invasive
means of identifying strain type in any disease state. In this sense,
and in contrast to the DNA-dependent techniques, serotyping
allows not only the inclusion of clinical, but also subclinical
cases. This is extremely important not only to provide a
means for early detection of toxoplasmosis before clinical signs
are established, but it also identifies the strain type infecting
asymptomatic individuals, which may provide new insight into
Toxoplasma epidemiology.
This so-called serological typing is based on the fact that many
host antibodies are raised against parasite proteins that are highly
polymorphic among distinct strains. Furthermore, Toxoplasma
stimulates a strong and persistent humoral immune response in
every host: antibodies to parasite proteins remain at high titers
for the life of the host and are present in patients regardless
of the clinical manifestations. In the last two decades, some
advances have been made in the development of these tests to
determine the strain from infected hosts by using polymorphic
parasite peptides (Dard et al., 2016). By coating ELISA plates,
nitrocellulose membranes, or glass slides with these polymorphic
peptides and monitoring the reactivity of the serum, a prediction
of the infecting strain type can be made. Several studies have
demonstrated the usefulness of such tests in different species
(Kong et al., 2003; Nowakowska et al., 2006; Peyron et al.,
2006; Morisset et al., 2008; Vaudaux et al., 2010; Maksimov
et al., 2012a,b, 2013, 2018; McLeod et al., 2012; Shobab et al.,
2013). However, although some attempts have been made to
differentiate the three archetypal strains (type 1, 2, and 3),
unfortunately, at the moment these methods can only reliably
distinguish type 2 from non-type 2 strains, typically type 1 or 3
(Kong et al., 2003; Sousa et al., 2009; Xiao et al., 2009; Maksimov
et al., 2012b, 2018; McLeod et al., 2012).
Since it is extremely unlikely that a single or only a few
peptides can distinguish strain types reliably, the identification
of a large number of peptides that allow for the detection
of the total diversity of existing strains would be a major
advancement in Toxoplasma serotyping. In the present study,
we validated previously described peptides, and identified
new Toxoplasma antigenic peptides that could be used to
discriminate between infections caused by different strain types
based on whole genome comparisons of the 64 Toxoplasma
strains available in ToxoDB (http://ToxoDB.org; Gajria et al.,
2008). In addition to these polymorphic peptides, we also
screened the antigenicity and specificity of peptide sequences
from genes expressed in some strains but absent in others.
It is worth mentioning that peptides, regardless of the strain
genotype, are able to provide a specific mark; hence they
may recognize clonal as well as recombinant strain types as
long as they possess the specific type sequence of the peptide.
Therefore, by increasing the number of peptides that can be
recognized by an individual serum, in the future a specific
“fingerprint” for each strain might be defined, similar to
current RFLP methods. This, in turn, will allow large studies
to be conducted that correlate peptide epitopes as markers
for infecting strains with specific disease outcomes, which
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may help to better understand how strain type influences
disease outcome.
METHODS
Toxoplasma in vitro Culture
Toxoplasma strains used for animal infections were routinely
maintained on Human Foreskin Fibroblast (HFF) monolayers in
Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies)
supplemented with 1% fetal bovine serum (FBS; Omega
Scientific), 4.5 g/liter D-glucose, L-glutamine and antibiotics as
previously described (Jensen et al., 2015).
Ethics Statement and Mice Infection
All mouse work was performed in accordance with the
recommendations in the Guide to the Care andUse of Laboratory
Animals (104) of the National Institutes of Health. The MIT
Committee on Animal Care (assurance no. A-3125-01) and the
Animal Care and Use Committee of the Intramural Research
Program of NIAID (Animal Study Protocol LPD22E) approved
all protocols, and all efforts were made to minimize unnecessary
distress to the animals. Human samples were used according to
the Committee on the Use of Humans as Experimental Subjects
(COUHES) application No. 0808002869.
Serum Samples
Different serum samples from mice, rabbits and human patients
were used in the present study.
Mouse Samples
Sera frommice chronically infected with type 1 RH; type 2ME49,
Prugniaud -Pru-, FORT, WIL; and type 3 CEP, VEG, and C56
were used (Kong et al., 2003). Depending on the strain, infection
was carried out by intraperitoneal injection of tachyzoites or oral
gavage of 3–10 cysts in a volume of 0.2ml. Animals were checked
every day to detect signs of illness such as rough hair coat, apathy,
or weight loss. Depending on the strain, sulfadiazine, alone, or in
combination with pyrimethamine, was added to drinking water
(0.4 and 0.2 mg/ml), either at the time of infection or upon
detection of clinical signs, to control the acute stage. The sera of
infected mice were collected at different time points according to
the severity of infection caused by specific strains.
Rabbit Samples
Serum samples from rabbits infected with RH (type 1), ME49
(type 2), VEG (type 3), and WIL (type 2) strains were a kind gift
from Dr. Steve Parmley, Palo Alto Medical Foundation.
Human Samples
Serum samples from infected patients genotyped either in France
(Center national de reference-Toxoplasmose Limoges France)
(Sousa et al., 2008, 2009) or in the United States (de-la-Torre
et al., 2013; Shobab et al., 2013) were used, as well as samples
from healthy infected individuals and OT patients from Brazil
but living in USA. Table 1 has all the human serum information.
Selection of Genes and Epitopes
The complete genome sequences of multiple Toxoplasma strains
are available in ToxoDB (http://ToxoDB.org; Gajria et al., 2008).
Because Toxoplasma polymorphisms are mostly bi-allelic (i.e.,
at each SNP there are often only two polymorphic nucleotides)
(Grigg et al., 2001), we searched for polymorphic proteins with
signal peptides (secreted or surface proteins are more likely
to be antigenic) when comparing Toxoplasma strains 1 vs. 2,
2 vs. 3 and 1 vs. 3. Fifty polymorphic genes were selected
from this comparison, including the virulence factors ROP5,
ROP18, ROP16, and GRA15, as well as other rhoptry (ROP8 and
ROP20) and dense granule proteins (GRA3, GRA5, GRA6, and
GRA7) (Supplemental Table 1). The type 1, 2, and 3 sequences
from the selected proteins were downloaded from ToxoDB and
protein alignments were made using ClustalX (Thompson et al.,
1997). Regions in those alignments that were polymorphic and
predicted to be antigenic (see below) were considered for peptide
synthesis. Besides polymorphic peptides, we picked peptides
derived from proteins that are expressed in one strain but not
in another strain. These candidates came from genes that were
previously found to be differentially expressed between different
strains using Toxoplasma RNAseq (Melo et al., 2013), along with
information from other groups on gene expression levels in type
1, 2, and 3 strains that is available on ToxoDB. The best example
of this is the ROP18 virulence gene, which is not expressed
in type 3 but highly expressed in types 1 and 2 (Saeij et al.,
2006). In total we tested peptides from 62 Toxoplasma genes,
present on each of its 14 different chromosomes. Peptides to be
synthesized were selected on the basis of the following criteria:
focusing on short regions of typically 8–12 amino acids close
to the N- or C-terminus, hydrophilicity (Kyte-Doolittle plots),
presence of β-turns (ChouFasman), and good antigenic and
surface probability indexes (Jameson-Wolf and Emini’s surface
plots) were considered. To predict potential antigenic peptides,
we used computer algorithms (available at http://ca.expasy.org/
tools/) that predict protein hydrophilicity and tendency to form
turns. In total, 950 peptides derived from these proteins, as well
as 53 control peptides (see below), were used in the present study
(Supplemental Table 1).
Peptide Arrays
To be able to screen large numbers of peptides for their
antigenicity and the ability to discriminate between distinct
Toxoplasma strains, an ABIMED peptide arrayer system (MIT
Biopolymer facility) was used to construct cellulose peptide
arrays each containing 600 peptide spots. This system consists of
a computer-controlled Gilson diluter and XYZ liquid handling
robot which allows the deposition on amino-PEG cellulose
membranes of individual activated amino acids resulting in
peptide formation. Each spot contains 20 nmol starting peptide.
As an internal control we included an alanine scan of the
haemagglutinin (HA) epitope (YPYDVPDYA) for which specific
monoclonal antibodies are available. Polymorphic peptides from
GRA5, GRA6, and GRA7, known to be able to discriminate
between infections with different strain types (Kong et al., 2003),
served as positive controls, while peptides from other pathogens
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TABLE 1 | Human serum samples employed in peptide arrays and ELISA.
Name Type Country Infection origin Array number References
Donor 1 NA Brazil Unknown 2, 4 This study
Donor 2 NA Brazil Unknown 4 This study
Patient 1 NA Brazil Unknown 2, 4 This study
Patient 2 NA Brazil Unknown 2, 4 This study
Patient 3 NA Brazil Unknown 4 This study
Patient 4 NA Brazil Unknown 4 This study
Patient 5 NA Brazil Unknown 4 This study
D83 1 USA Ocular 4, 5 This study
NS 2 USA Lab accident 4 This study
TIL 3 USA Lab accident 4, 5 This study
IPP005-URB B (IppUrbB) 16 France Imported horse-meat consumption
(reinfection)
5 Elbez-Rubinstein et al., 2009;
Lorenzi et al., 2016
TyI FAJI 1 France Congenital 5 Ajzenberg et al., 2002
TyII Fr2a 2 France Unknown 5 Sousa et al., 2008
TyII Fr4b 2 France Unknown 5 Sousa et al., 2008
TyII Fr17b 2 France Unknown 5 Sousa et al., 2008
TyIII Fr18a (NED) 3 France Congenital 5 Sousa et al., 2008, 2009
TyIII Fr19a 3 France Unknown 5 Sousa et al., 2008, 2009
TyIII Fr20a (TOU-FEU) 3 France Unknown 5 Sousa et al., 2008, 2009
MAS 4 France Imported horse-meat consumption 5 Gallego et al., 2004; Pomares et al.,
2011
TOU021-ALI (TOU-ALI) 4 Reunion Island (France) Unknown 5 Gallego et al., 2004; Sousa et al., 2008;
Su et al., 2012
GUY014-TER (GUY-TER) Atypical Suriname Unknown 5 Sousa et al., 2008, 2009
VAND 10 French Guiana (France) Unknown 5 Gallego et al., 2004; Lorenzi et al., 2016
NA, not available.
were included as negative controls (Reineke et al., 2002; Weiser
et al., 2005; Albert et al., 2008) (Supplemental Table 1).
A total of 5 different arrays were carried out, containing 597,
300, 100, 120, and 40 peptides, respectively. For the first three
arrays, serum samples from chronically infected mice infected
with type 1, 2, or 3 strains were used. In addition, sera from
experimentally infected rabbits were also used in array 3. Finally,
human samples from healthy donors that tested positive for
Toxoplasma were used in array 2, whereas serum samples from
OT patients, as well as from infected patients with a genotyped
Toxoplasma strain, were used in arrays 4 and 5 (Table 1). Serum
samples from uninfected healthy mice and humans served as
negative controls. The first two arrays were used to find peptides
that were antigenic, while the other three were used to refine
promising peptides using a suite of type-specific serum samples
from human patients.
The protocol to detect antibody binding to specific peptides
was similar to a traditional Western blot. In short, the peptide
array was placed in a container and blocked overnight with
5% BSA, 5% dry milk, 0.1% Tween-20 PBS. Subsequently,
diluted serum (1/100–400, adjusted depending on the titer)
was added and after 2 h incubation the blot washed (0.1%
Tween-20 PBS). Then, an HRP-conjugated secondary antibody
(goat α-mouse, α-human or α-rabbit, 1/10,000, Sigma) was
added for 1 h after which the blot was thoroughly washed.
Upon addition of the substrate (West Dura Extended Duration
Chemiluminescent Substrate, Thermo Scientific) the signal was
detected using a chemidoc XRS molecular imager (Bio-Rad)
and spots individually quantified. To measure the intensity
of reaction for each peptide, either a visual quantification
was made on a scale from 0 (absent) to 5 (very strong) or
a densitometric analysis of the signals was performed using
Quantity One quantification analysis software (Bio-Rad). In
the first array, because a high number or peptides were
used (597), and since peptide arrays can be stripped using
aqueous chaotropes (Abcam), the same membrane was used
with three different serum samples. Nevertheless, to reduce
non-specific background derived from stripping, in the 4
subsequent arrays, instead of testing the different samples in
the same membrane after stripping, groups of peptides were
spotted repeated times (6 in the second array, 9 in the third
array, 10 in the fourth array, and 15 in the fifth array),
membranes were cut into pieces, and each piece tested with a
different serum.
Statistical Analysis
A contingency table was created and a chi-squared (χ2) test
was performed in the GRA7 peptide ELISA. A p < 0.01 was
considered as significant.
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RESULTS
Peptide Arrays Identify Novel Antigenic
and Strain-Specific Peptides
Five peptide array assays were performed in this study. The
initial arrays aimed to identify polymorphic peptides that were
antigenic (i.e., react well with sera frommice infected with at least
one strain).
The first array contained 597 peptides, including an alanine
scan of the HA peptide as a positive control. Mouse sera from
type 1 (RH), 2 (Pru), and 3 (CEP) infected mice and uninfected
mouse serum as a negative control were used. As expected,
there was strong reactivity against the intact HA peptide after
incubation with an anti-HA monoclonal antibody, which was
not affected when the amino acid was changed to an alanine
at positions 5 or 6, but was almost completely abrogated when
it was changed in the other positions (Figure 1A). From this
control it was clear that polymorphisms at certain sites in a
peptide do not affect serum reactivity, whereas mutations at
other sites abrogate reactivity. To identify antigenic peptides, we
pinpointed those that reacted strongly to one or several serum
samples from the different types (Figures 1B–E). Eighty-three
peptides from 26 different Toxoplasma proteins reacted strongly
with at least one serum (score of at least 4, where 0 is absence of
reaction and 5 the strongest reaction, see materials and methods)
(Supplemental Table 2). While the majority of these 83 peptides
were type-specific, 11 shared reactivity between types (4 reacted
with both I and III whereas 7 reacted with both II and III sera)
(Figure 1F). Some proteins, such as GRA3, GRA5-8, GRA15,
ROP1, ROP18, SAG1, and SAG2A are known to be immunogenic
and epitopes from these proteins were evaluated previously
for their seroreactivity (Supplemental Table 1). In addition,
peptides from novel antigenic proteins also reacted strongly
to one or several serum samples, including GRA9, GRA31,
ROP9, ROP10, ROP16, ROP19A, ROP20, ROP25, ROP26,
ROP39, ROP47, TEEGR, Toxofilin, a histidine acid phosphatase
superfamily protein (TGME49_308950), a putative oocyst
wall protein (OWP, TGME49_222940), and one hypothetical
protein (TGME49_268790) (Supplemental Table 2). Although
our objective for this initial array was to identify immunogenic
peptides, strain-specific peptides were also found. Forty-eight of
the 83 antigenic peptides reacted to serum in a strain-specific
manner with a reactivity score between strain types that differed
by at least 3.5, however, only 15 of these polymorphic peptides
reacted according to their strain type. In all, a total of 29
peptides reacted stronger with their type-specific serum, having
FIGURE 1 | A Toxoplasma peptide array detects novel antigenic peptides. (A) HA-tag alanine-scan control. Reactivity of different Alanine-variants of the HA-tag
epitope was measured with an HA-specific antibody. In bold, full HA amino acid sequence. In red, alanine substitutions. (B) A nitrocellulose membrane coated with
597 different peptides was blocked and incubated with serum from mice chronically infected with Pru (type 2) strain. After washing, the array was incubated with
anti-mouse HRP antibody, washed, and incubated with luminescent substrate. Luminescent signal was detected using a CCD camera (shown as dark round spots or
when signal was really strong and saturated as bright white spots). The membrane was subsequently stripped and then incubated again with (C) CEP (type 3), (D) RH
(type 1), and (E) uninfected mouse serum, following the same procedure as described above. The peptide positions are indicated by numbers above each column
(representing the number of the first peptide of the column) and on the left of each row (indicating the peptide position as a reference for each one of the columns). For
instance, the dot on the intersection of the column named 81 and the row named 12 would be peptide number 92. Note the strong reactivity of several peptides
(marked with red circles). For details on each peptide sequence readers are referred to Supplemental Table 2. (F) Venn diagram showing the number of specific and
shared reactive (visual score ≥4) epitopes between type 1, 2, and 3 strains. Numbers in parenthesis indicate the proportion of specific peptides derived from novel
proteins not previously used for serological assays.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5 November 2019 | Volume 9 | Article 408
Arranz-Solís et al. Toxoplasma Peptide Array Serotyping
a reactivity score >3.5, whereas their non-type reactivity score
was equal or inferior to 2.5, indicating that the peptide was
immunogenic across strains. Among these, type 1, 2, 3, 1/2, 1/3,
and 2/3 specific peptides were identified (Supplemental Table 2).
In addition, the uninfected serum sample was unreactive to all
peptides except for three ROP16 peptides, which showed non-
specific reactivity (Figure 1E).
To optimize the assay, new peptides were selected to construct
a second array with 300 spots, using type 1 (RH), 2 (ME49),
and 3 (VEG) murine sera and 3 human serum samples from
infected but healthy donors. We removed those peptides that
showed a weak reaction in array 1 and redesigned previous
peptides developed for serotyping in an effort to improve
their reactivity by making them shorter or by altering left
or right the register of the peptide in a stepwise fashion. A
complete display of the array comparing reactivity with sera
from mice infected with type 1, 2, and 3 strains is shown in
Figure 2A and Supplemental File 1. Eighty peptides that reacted
strongly (visual score ≥4) to at least one of the mouse samples
were identified (Supplemental Table 2). Apart from the proteins
described in array 1, peptides from ROP5, 8, 17, and 19A; 2
hypothetical proteins (TGME49_200360 and TGME49_308970),
a reticulon protein (TGME49_226430), and a zinc finger
(CCCH type) motif-containing protein (TGME49_242090) were
identified. Moreover, 16 of these 80 peptides showed strong
type-specific reactivity (at least 3.5 difference between types).
Namely, peptides derived from GRA6, GRA7, SAG2A, ROP16,
toxofilin, and TGME49_268790. In addition to confirming
the validity of previous strain-typing peptides, new peptides
were identified that accurately predicted the infecting strain
(Figure 2A). These included peptides from ROP16 (pos. 160),
ROP18 (pos. 27), ROP19A (pos. 10), ROP20 (pos. 276), SAG1
(pos. 125), and toxofilin (pos. 197, 200 and 203) (Figure 2A and
Supplemental File 1).
Moreover, this array allowed us to define the optimum,
minimal antigenic peptides for GRA6 and GRA7. For example,
by analyzing the reactivity of the type 3 GRA7 peptides 43 and 45
from Kong et al. (2003) against a suite of new peptides within
that antigenic region, we concluded that the minimal peptide
52, ESGEDREDAR was sufficient to bind type-specific antibodies
with both specificity and sensitivity from type 3 infection serum
(Table 2, Figure 2B, arrows). Indeed, peptide 52 possessed the
same strong reactivity that was observed in peptides 43 (which
contained two extra N-terminal amino acids and an extra C-
terminal amino acid, VP and Q, respectively) or 45 (peptide 43
but lacking the two final amino acids RQ). Similarly, the type 2
GRA7 peptides 41, 44, and 51 revealed that VP was not needed
for strong reactivity using type 2 sera, although in this case the
final amino acids seemed to exert influence, as peptide 44 had
reduced, but still high, reactivity against type 2 serum (Table 2,
Figure 2B, arrowheads). Our high throughput array was also able
to pinpoint relevant polymorphisms between types that appeared
to be more important for strain specificity. For example, the
GRA7 type 1/2 peptide 56 originally described by Kong et al.
(2003) had a much stronger reaction with types 1 and 2 sera,
whereas the type 3 version, peptide 57, had a much stronger
reaction with type 3 serum (Figure 2B). Similarly, the GRA6 type
2 peptide number 81 had a strong reactivity with type 2 and the
type 3 peptide number 87 with type 3 sera, as observed previously
(Kong et al., 2003) (Figure 2C).
Finally, a further analysis of this array was carried out by
incubating the membrane with 3 different human samples from
infected healthy patients (Supplemental Figure 1). Although
the strain causing the infection was unknown, 40 peptides
reacted strongly to one or more of the samples with a visual
score ≥4. Among these, we found peptides derived from
GRA3, GRA5, GRA6, GRA8, GRA31, ROP1, ROP8, ROP16,
ROP39, ROP47, SAG2A, and Toxofilin (Supplemental Table 2
and Supplemental Figure 1). From these proteins, some peptides
from GRA8, GRA31, ROP1, ROP47, and Toxofilin reacted
strongly only with human, but not mouse, serum samples.
GRA6 and GRA7 C-Terminal Peptides
Show 13 Different Sequence Combinations
Because the GRA6 and GRA7 peptides showed promising results,
we analyzed the amino acid sequences from the 64 strains
available on ToxoDB for the C-terminal region (the last 11 and
13 aa, respectively) for these two proteins. This allowed us to
determine the possible sequence combinations that give rise
to different allele groups (Table 3). For the GRA6 C-terminal
region, a total of 6 different 11-aa peptides were identified. The
antigenicity of these 6 different possible GRA6 peptides has
been previously reported to be different (Vaudaux et al., 2010).
On the other hand, only three possibilities were observed for
the GRA7 C-terminal 13-aa peptide. When both peptides were
aligned together, a total of 13 unique combinations were detected
for the 64 strains available in ToxoDB (Table 3). This clearly
indicates that different strain genotypes belonging to different
haplogroups can share the same amino acid sequence within
these immunogenic epitopes. For instance, the type 2 strains
ME49 and PRU are genotypically distinct fromMAS, TgCatBr25,
B41, and GAB5-2007-GAL-DOM6 [Haplogroups 4, 8, 12, and
14 respectively (Lorenzi et al., 2016)], but they possess the same
GRA6 sequence, hence the atypical strains would be predicted
to have type 2 reactivity for this peptide. Equally, the type 3
strains VEG and CEP are genotypically distinct from MAS,
CAST, TgCatBr5 and TgCatBr44 (Haplogroups 4, 7, 8, and 10
respectively), but they possess the same GRA7 sequence, so the
atypical strains would be predicted to have type 3 reactivity at
this peptide. Accordingly, all available GRA6 andGRA7 sequence
combinations, when analyzed together, identify 13 different
combinations that should be able to separate type 1 from 2 from
3 from 12 clonal type infections (Table 3).
Moreover, the arrays showed that some peptide regions
in particular proteins are antigenic in some strains, but
not for others. For example, type 1 mouse serum did not
react to the type 1 GRA7 peptide CVPESGEDGEDARQ,
whereas type 2 and 3 serum samples reacted strongly to the
type 2 (CVPESGKDGEDARQ) and 3 (CVPESGEDREDARQ)
versions of the peptide, respectively. By contrast, type 1
serum reacted strongly against a different GRA7 peptide
(type 1 ELTEEQQRGDEPL), whereas the type 3 serum
only reacted weakly against the equivalent type 3 version
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FIGURE 2 | A second Toxoplasma peptide array detects many new strain-specific peptides. (A) Nitrocellulose membranes coated with 300 peptides was blocked
and incubated with serum from mice chronically infected with RH (type 1, top left), ME49 (type 2, top middle), and VEG (type 3, top right) strains. After washing, the
array was incubated with anti-mouse HRP antibody, washed, and incubated with luminescent substrate. Luminescent signal was detected using a CCD camera
(shown as dark round spots or when signal was really strong and saturated as bright white spots). The peptide positions are indicated by numbers above each
column (representing the number of the first peptide of the column) and on the left of each row (indicating the peptide position as a reference for each one of the
columns). For details on each peptide sequence readers are referred to Supplemental Table 2. (B) Comparison of the third column of each membrane showing
peptides 41–60 corresponding to different parts of GRA7 incubated with the different strain sera (indicated by numbers over each membrane strip). For each peptide
the sequence is indicated and what strain(s) have that sequence. Type 3 peptides 43, 45, and 52 (arrows), and Type 2 peptides 41, 44, and 51 (arrowheads) are
marked as examples to indicate the minimal antigenic peptide that confers a strong antigenicity (underlined). Peptide 52, which was further analyzed by ELISA
(Figure 4), is marked with a box. (C) Comparison of the fifth column of each membrane showing peptides 81–100 corresponding to different parts of GRA6 incubated
with the different strain sera (indicated by numbers over each membrane strip). For each peptide the sequence is indicated and what strain(s) have that sequence. P,
peptide. An asterisk (*) indicate peptides already described by Kong et al. (2003). Readers are referred to Supplemental Table 2 for further details.
(ELTEQQQTGDEPL) (Figure 2B). Altogether, this suggests that
the antibody response is focused on different regions of a protein
in an epitope-dependent manner, which serves the diagnostic
genotyping purposes.
Optimization of Promising Peptides
For the third array, 100 peptides that reacted strongly and/or
specifically in array 2 were repeated, some of them slightly
modified (Supplemental Table 1), and tested using a panel of
sera from mice infected with RH (type 1), FORT (type 2),
WIL (type 2), and C56 (type 3), and rabbits infected with RH
(type 1), ME49 (type 2), WIL (type 2), and VEG (type 3). A
complete display of the third array comparing reactivity with
sera from mice and rabbits is shown in Supplemental File 2.
A strong reactivity (>40,000 integrated density) was observed
for 32 and 27 peptides when incubated with mouse and rabbit
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 7 November 2019 | Volume 9 | Article 408
Arranz-Solís et al. Toxoplasma Peptide Array Serotyping
TABLE 2 | Several versions of GRA6 and GRA7 peptides show the importance
that specific amino acids have in serum reactivity to these peptides.
Visual score
Peptide sequence Type Spot # Type 1 Type 2 Type 3
GRA6
CLHPGSVNEFDF 2 80 3 4.5 3.5
CLHPGSVNEFD 2 81 2.5 4.5 2.5
CPGSVNEFDF 2 82 3.5 3.5 3.5
CLHPGSVNE 2 83 2 3.5 2
CLHPERVNVFDY 1/3 77 1 1 5
CLHPERVNVFD 1/3 79 2.5 2 5
CLHPERVNV 1/3 78 1.5 1 2.5
GRA7
CVPESGKDGEDARH 2 41 1 4.5 2
CESGKDGEDAR 2 51 1 5 2
CVPESGKDGEDA 2 44 1 3.5 0.5
CVPESGEDREDARQ 3 43 1 3 5
CVPESGEDREDA 3 45 0.5 2 4.5
CESGEDREDAR 3 52 1 2 4.5
GRA6 and GRA7 peptide sequences and strain type used in the second array are shown
together with the visual score when tested with type 1, 2, and 3 mouse sera. Red letters
in the peptide sequences mark amino acids that differ between strains. Red numbers in
the visual scores mark the expected type serum to react for each peptide.
sera, respectively. Among these, peptides from GRA3, GRA6,
ROP1, ROP5, ROP16, ROP17, ROP18, ROP20, SAG2A, and
TGME49_200360 reacted strongly in both mouse and rabbit
serum samples. Moreover, some peptides were able to specifically
recognize type 1 (ROP16 in rabbits), type 2 (GRA3, GRA5,
GRA6, and GRA7 in mice; GRA3, SAG3, and ROP16 in rabbits)
and type 3 (GRA5, GRA7, and ROP16 in mice) serum samples
(Supplemental Table 2 and Supplemental File 2).
In the fourth array, we repeated some of the better peptides
and redesigned others from the previous arrays. OT patients
and healthy infected donor samples were used to test this
array containing 120 peptide sequences (Supplemental File 3).
Thirty-five peptides showed a strong reactivity (≥4 visual score),
while 25 peptides reacted to at least 2 of the 10 samples with
a visual score ≥3. Strong reactive peptides derived mainly
from GRA (3, 5–9, 14–15) and ROP (5, 8, 16–18, 19A, 20,
26, 39–40) proteins, as well as SAG1, SAG3, one hypothetical
protein (TGME49_268790), Toxofilin and a zinc finger (CCCH
type) motif-containing protein (TGME49_242090). Among
these, peptides on position 42 (GRA15), 71 (ROP8), and 93
(TGME49_242090) reacted strongly to several of the samples
tested (Supplemental Table 2 and Supplemental File 3). In
addition, it is worthmentioning that two of the samples, Patient 5
and Donor 2, despite possessing similar titers as that found for all
sera tested by ELISA against whole antigen, did not react to any of
the 120 peptides from this array with a visual score of 3 or more.
Only 2 peptides were able to elicit a reaction with a visual score of
2.5 in Patient 5: ROP19A (position 105) and ROP8 (position 74).
By contrast, Donor 1 showed a high reactivity (visual score of 3
or more) with 44 of the 120 peptides (Supplemental Table 2 and
Supplemental File 3). All sera samples were titered into the same
range (1/1200-1/4800) using whole Toxoplasma antigen to avoid
significant differences in the antibody levels. Hence, differences
in reactivity could not be simply attributed to each sample’s titer.
Finally, the fifth array was made with the same or slightly
different sequences from the 40 best peptides in the previous
arrays, and a total of 14 serum samples from which the strain
causing the infection is known, as well as a few unknown
human serum samples were used. A complete display of the fifth
array comparing these samples is shown in Supplemental File 4.
From the 40 tested peptides, 18 showed a visual score of ≥4.
These peptides were derived from GRA (3, 5–8, 15) and ROP
(8, 19A, 20, 39) proteins. In addition, 13 peptides reacted
with at least 3 of the samples with a visual score of 3.5 or
higher, including, apart from the above mentioned, a ROP26
derived peptide. Moreover, 2 of the 15 samples (VAND and III-
Fr20a) did not react to any of the peptides with a visual score
higher than 3.5, and only a TEEGR (position 25) and a GRA3
(position 1) peptide reacted with a visual score of 3.5 against
VAND and IIIFr20a, respectively (Supplemental Table 2). As
described for array 4, titers were similar among all samples
used in this array and different dilutions were made to ensure
similar levels of antibodies were present in all the samples.
Unfortunately, the last two arrays using human serum did
not detect strain-specific peptides able to accurately predict
the genotype of the human infection for all of the human
samples used. Nevertheless, when a visual score of 2.5 was
considered as a cut-off, a number of peptides derived from
GRA3, 5, 6, and 7 predicted the strain in several serum
samples (Figure 3). From the 14 serum samples, 8 were correctly
predicted, 3 did not react to any of the selected peptide above
the cut-off limit and the remaining 3 had mixed reaction
that rendered the prediction inconclusive. Moreover, and in
contrast to archetypal strains, IppUrbB, MAS and GUY-TER
serum samples reacted strongly to different versions of the
same peptide. IppUrbB sample was a case of reinfection in
a pregnant woman leading to congenital infection (Elbez-
Rubinstein et al., 2009) that was later identified as haplogroup
16 by microsatellite markers and whole genome sequencing
(Lorenzi et al., 2016). Hence there was a mixture of reactions to
several peptides.
A Novel GRA7 Peptide Specifically Detects
Type 3 Infections
Overall, the arrays carried out trying different versions of the
same peptides with different serum samples allowed us to identify
a large number of antigenic and strain-specific peptides using
the peptide array approach. These were derived from several
proteins, many of which are described here for the first time to
have diagnostic potential. However, arrays are not always readily
available, they are expensive and are not easily transferable
to other laboratories. Hence, as a proof-of-concept, we tested
the ELISA protocol originally used for serotyping type 2 from
non-type 2 infections (Kong et al., 2003). The array identified
a delimited version of a type 3-specific peptide from GRA7
(ESGEDREDAR) that could distinguish type 3 from type 1 and
2 infections (Figure 2B, position 52). To confirm this prediction,
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TABLE 3 | Amino acid sequence alignment from GRA6 and GRA7 C-terminal region in the 64 strains available on ToxoDB shows the possible combinations that give rise
to different allele groups.
Strains (ToxoDB) GRA6 sequence No. strains
(ToxoDB)
Alignment
VEG, TgShUS28, TgRsCr1, TgDogCo17, TgCtCo5,
TgCatPRC3, TgCkBr141, TgCkCr1, TgCkCr10,
TgCatBr72, TgCatBr26, BOF, SOU, ROD, VAND,
RH-JSR, RH-88, RH, M7741, GUY-2003-MEL, GT1,
GAB5-2007-GAL-DOM1, GAB3-2007-GAL-DOM2,
CAST, BRC_TgH_18021, BRC_TgH_18003_GUY-MAT,
BRC_TgH_18002_GUY-KOE,
BRC_TgH_18001_GUY-DOS, TgCatBr9, FOU
LHPERVNVFDY 30
COUG, RAY, GUY-2004-JAG1, ARI, BRC_TgH_21016 LHPERVNEFDY 5
TgCatBr1, TgCatBr3, TgCatBr44, BRC TgH 18009 LHPEHVNVFDY 4
RUB LHLERVNAFDY 1
p89, GUY-2004-ABE, TgCatBr10, TgCatBr15,
TgH26044, TgCkGy2, TgCatBr64, TgCatBr34,
BRC_TgH_20005, CASTELLS, G662M. (GUY-TER,
TOU-ALI and IppUrbB)
LHPGSVNVFDY 11
PRU, TgCatBr18, TgCatBr25, TGME49, TgCATBr5,
TgCat_PRC2, MAS, GAB5-2007-GAL-DOM6,
GAB3-2007-GAL-DOM9, GAB2-2007-GAL-DOM2,
GAB1-2007-GAL-DOM10, B41, B73
LHPGSVNEFDF 13
Strains (ToxoDB) GRA7 sequence No. strains
(ToxoDB)
Alignment
TGME49, PRU, SOU VPESGKDGEDARQ 3
TgShUS28, TgDogCo17, TgCkGy2, TgCkCr1,
TgCkBr141, VAND, COUG, RAY, TgCat_PRC2, BOF,
TgCatBr15, RH-JSR, RH-88, RH, GUY-2003-MEL, GT1,
GAB5-2007-GAL-DOM6, GAB5-2007-GAL-DOM1,
GAB3-2007-GAL-DOM9, GAB3-2007-GAL-DOM2,
GAB2-2007-GAL-DOM2, GAB1-2007-GAL-DOM10,
FOU, GUY-2004-ABE, BRC_TgH_18001_GUY-DOS,
RUB, BRC_TgH_18021, BRC_TgH_18009,
BRC_TgH_18002_GUY-KOE,
BRC_TgH_18003_GUY-MAT, GUY-2004-JAG1, ARI,
B41. (GUY-TER and TOU-ALI)
VPESGEDGEDARQ 33
p89, VEG, TgRsCr1, TgCtCo5, TgCatPRC3, TgCatBr64,
TgCatBr3, TgH26044, TgCatBr72, TgCatBr44,
TgCatBr34, B73, TgCkCr10, ROD, M7741, G662M,
CASTELLS, CAST, BRC_TgH_21016, MAS, TgCATBr5,
TgCATBr9, TgCatBr1, TgCatBr10, TgCatBr18,
TgCatBr25, TgCatBr26, BRC_TgH_20005. (IppUrbB)
VPESGEDREDARQ 28
Strains (ToxoDB) GRA6///GRA7 sequence No. strains
(ToxoDB)
Alignment
RH, RH-88, RH-JSR, GT1, FOU, BOF,
BRC_TgH_18002_GUY-KOE, TgCkCr1, TgCkBr141,
TgShUS28, TgDogCo17, BRC_TgH_18003_GUY-MAT,
BRC_TgH_18021, BRC_TgH_18001_GUY-DOS,
GAB3-2007-GAL-DOM2, GAB5-2007-GAL-DOM1,
GUY-2003-MEL, VAND
LHPERVNVFDY///VPESGEDGEDARQ 18
BRC_TgH_18009 LHPEHVNVFDY///VPESGEDGEDARQ 1
(Continued)
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 9 November 2019 | Volume 9 | Article 408
Arranz-Solís et al. Toxoplasma Peptide Array Serotyping
TABLE 3 | Continued
Strains (ToxoDB) GRA6///GRA7 sequence No. strains
(ToxoDB)
Alignment
ARI, RAY, COUG, GUY-2004-JAG1 LHPERVNEFDY///VPESGEDGEDARQ 4
GUY-2004-ABE, TgCatBr15, TgCkGy2 LHPGSVNVFDY///VPESGEDGEDARQ 3
RUB LHLERVNAFDY///VPESGEDGEDARQ 1
GAB1-2007-GAL-DOM10, GAB2-2007-GAL-DOM2,
GAB3-2007-GAL-DOM9, GAB5-2007-GAL-DOM6,
TgCat_PRC2, B41
LHPGSVNEFDF///VPESGEDGEDARQ 6
BRC_TgH_21016 LHPERVNEFDY///VPESGEDREDARQ 1
VEG, CAST, M7741, ROD, TgRsCr1, TgCATBr9,
TgCatBr26, TgCatBr72, TgCkCr10, TgCtCo5,
TgCatPRC3
LHPERVNVFDY///VPESGEDREDARQ 11
SOU LHPERVNVFDY///VPESGKDGEDARQ 1
p89, BRC_TgH_20005, CASTELLS, G662M,
TgH26044, TgCatBr34,TgCatBr64, TgCatBr10
LHPGSVNVFDY///VPESGEDREDARQ 8
MAS, B73, TgCatBr18, TgCatBr25, TgCATBr5 LHPGSVNEFDF///VPESGEDREDARQ 5
ME49, Pru LHPGSVNEFDF///VPESGKDGEDARQ 2
TgCatBr1, TgCatBr3, TgCatBr44 LHPEHVNVFDY///VPESGEDREDARQ 3
The different possible sequences of GRA6 (above), GRA7 (middle) and a combination of both (bottom) are aligned and a representative strain from each group is given, where dots
indicate identical amino acids. Red letters in the second column mark amino acids that differ between strains groups.
FIGURE 3 | Serotyping results for human serum samples using a combination of different GRA3, GRA5, GRA6, and GRA7 peptides. The strain that caused the
infection for each sample is shown and the visual score is indicated for each peptide, being 0 absence of reaction, and 5 the strongest reaction. A prediction for each
sample is made based on the results obtained for each peptide. IC, inconclusive; NR, non-reactive.
the peptide was tested against a broad panel of type-specific
serum samples from mice, rabbit, and human from which the
infecting strain was known. To this end, a cysteine residue
was added to the C terminus so that it could be coupled to
the carrier protein keyhole limpet hemocyanin (KLH) and it
was synthesized as a soluble peptide. The ELISA results show
that the delimited GRA7 peptide was able to accurately detect
type 3 infections in mouse, rabbit and human samples (χ2
20.29, p < 0.0001) (Figure 4) with high specificity, confirming
the results observed in the second peptide array (Figure 2B).
Indeed, 16 type 3 serum samples reacted to this peptide, with
only 2 rabbit, 1 mouse and 1 human type 3 samples falling
below the cut-off limit. No type 1 or 2 serum samples from
any species reacted to this peptide indicating that it was both
highly specific, with no false positives detected, and 80% sensitive,
with only 4 false negatives. Furthermore, 3 out of 4 false
negatives were from infections with the VEG strain, which
could suggest a specific non-reactivity for this allelic epitope
upon infection with this strain. Additionally, CAST, which is
not a Type III strain, had a type 3 sequence at the GRA7
peptide epitope (Table 3) indicating that antibodies were not
dependent on the allele present at GRA7, but rather on the
epitope sequence, which is why CAST serotyped as type 3
at GRA7.
DISCUSSION
Toxoplasma gondii is known to cause a wide spectrum of
clinical presentations in animals and humans, ranging from
asymptomatic to severe, even lethal, disease. Besides the host
immune response, it is known that strain type is one of the key-
factors responsible for the clinical appearance of toxoplasmosis
(Boothroyd and Grigg, 2002; Kong et al., 2003). To develop
a rapid, sensitive and non-invasive method of identifying
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FIGURE 4 | A novel GRA7 peptide identifies type 3 strain infections with high specificity and sensitivity. Our peptide arrays identified a GRA7 peptide that worked well
in distinguishing infections with type 3 strains and was therefore synthesized, coupled to KLH and loaded into an ELISA plate. Sera from mice, rabbits (RB), and
humans (HU) infected with types 1 (I), 2 (II), or 3 (III) strains was added and (A) binding was detected using an HRP-conjugated secondary antibody using ELISA assay
according to Kong et al. (2003). The peptide has high specificity with no false positives detected, however four type 3 sera failed to react (indicated by *). OD, Optical
Density. Cut-off value was 1.4, above which samples were considered positive. (B) GRA7 peptide sequences for the three archetypal strains.
strain type, serotyping has been shown to provide a promising
alternative to the not always possible, difficult and often risky
biopsy-based DNA methods (Kong et al., 2003; Vaudaux et al.,
2010). Indeed, several studies have employed synthetic peptides
or recombinant polypeptides from polymorphic regions to
serologically predict the clonal type of T. gondii responsible
for the infection, showing that in hosts such as cats, mice,
chickens, turkeys, pigs, sheep, or humans it is possible to reliably
distinguish type 2 from non-type 2 infections (Kong et al., 2003;
Peyron et al., 2006; Morisset et al., 2008; Sousa et al., 2009, 2010;
Xiao et al., 2009; Vaudaux et al., 2010; Maksimov et al., 2012a,b,
2018; McLeod et al., 2012; Hutson et al., 2015). In addition, some
studies attempted to develop peptides able to differentiate type 1
vs. 3 and type 2 vs. 3 infections with partial success (Xiao et al.,
2009; Maksimov et al., 2012a, 2018). However, to date, a clear
serotyping distinction between type 1, 2 and 3 strains, as well as
those from non-archetypal strains, has not been possible.
In the present study a total of 950 peptides from 62 different
polymorphic or differentially expressed Toxoplasma proteins
were analyzed. For this, a large-scale peptide array assay was used
to test different peptides with mice, rabbit and human sera, which
allowed us to identify the most antigenic peptides. Some of these,
such as GRA1, 3, 5–8, and 15; ROP1, 5, 8, 9, and 18; and SAG1,
2A, 3, have been already reported to be highly antigenic and
proved useful in different Toxoplasma serodiagnostic techniques
(e.g., Beghetto et al., 2003; Kong et al., 2003; Grzybowski
et al., 2015). However, we describe here for the first time
the potential use of a large number of immunogenic peptides
derived from proteins that have never been used for serodiagnosis
purposes before, such as GRA9, GRA31, ROP10, ROP16, ROP20,
ROP25, ROP26, ROP38, ROP39, or toxofilin, among others
(Supplemental Tables 1, 2). Unsurprisingly, peptides derived
from GRA5, 6 and 7 were the most reactive, which correlates
with the high potential of dense granule proteins as diagnostic
antigens shown in previous works (e.g., Maksimov et al., 2012a).
Moreover, our results revealed a number of peptides with the
ability to discriminate between mice infected with different
type 1, 2 and 3 strains. As mentioned above, peptides able to
distinguish type 2 vs. non-type 2 (Kong et al., 2003), type 1
vs. type 3 (Xiao et al., 2009), and type 2 vs. type 3 (Maksimov
et al., 2012a) infections were previously described. Herein, to
the best of our knowledge, we describe for the first time peptide
combinations with the potential of differentiating type 1 vs. type
2 (e. g. GRA7, ROP17, and ROP18), as well as novel peptides that
also successfully discriminate type 1 vs. 3 (e.g., SAG2A, ROP20,
and Toxofilin) and 3 vs. non-3 (e.g., GRA7 and ROP19A).
These new peptides warrant further investigation using a broader
panel of serum samples from different animals and conditions
to test their ability to efficiently discriminate between infections
caused by different Toxoplasma strains. Nevertheless, the final
objective of Toxoplasma serotyping is arguably aimed to assist
in human toxoplasmosis, and as such we included human
samples in our arrays. However, because the human sera were
available in limited quantities, they were not used for the initial
screening of large numbers of peptides. Therefore, the usage of
genotyped human patients was restricted to the last arrays in
which the selection of peptides was narrowed down. A large
number of peptides were very immunogenic in humans, and
most of these were also antigenic in mice. Unfortunately, none
of the peptides tested in the final arrays were able to accurately
discriminate all patients infected with different strains. Hence,
a further investigation with a broader panel of characterized
samples from patients is needed. Nonetheless, when a panel of
GRA3, GRA5, GRA6, and GRA7 peptides were selected using
a lower cut-off, several human serum samples were correctly
predicted. As reported by others (e.g., Kong et al., 2003; Sousa
et al., 2008) patients infected with non-archetypal strains such
as MAS, GUY-TER, and IppUrbB often possess strong reactions
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with peptides harboring type 1, 2, and/or 3 lineage sequences.
However, upon closer examination, MAS, which has a type 4
genotype, possesses type 2 peptide epitopes at GRA6 and GRA7,
which is why it produces a type 2 serotype. In comparison,
serum from IppUrbB, a pregnant woman that became re-
infected during gestation leading to congenital transmission
(Elbez-Rubinstein et al., 2009), possessed dual reactivity because
the second infecting strain was later identified to belong to
haplogroup 16 (Lorenzi et al., 2016), which explained her mixed
reactivity serotyping pattern. It is worth mentioning that the
serotyping methodology showed a high degree of individual
variability for some peptides depending on the strain initiating
infection. In fact, several peptides that reacted strongly to serum
from mice infected with the corresponding peptide epitope, also
reacted with sera from animals infected with strains that did not
possess the cognate peptide sequence. By contrast, other peptides
were only weakly recognized by a limited number of sera from
animals infected with strains that had the respective type-specific
peptide sequence. Because of this mixture of cross-reactivity
and/or low sensitivity, just as PCR-RFLP for a single locus cannot
determine strain type, serotyping undoubtedly requires a large
number of polymorphic peptides from different antigens to be
analyzed as a whole, instead of relying on individual peptides,
to provide a serological profile or signature that defines a strain
type (Sousa et al., 2008; Vaudaux et al., 2010; Maksimov et al.,
2012a). Likewise, we observed a small proportion of human sera
that did not react to any of the peptides tested, whereas other
sera reacted strongly to a high number of peptides. Since the
titer of the samples were similar and dilutions were performed
accordingly, it is unlikely that this was due to differences in the
level of antibodies. The great individual variability in human
samples detected here is in accordance with previous reports
(Kong et al., 2003; Sousa et al., 2009;Maksimov et al., 2012a). This
may be due to the different conditions of individual patients, such
as immunocompetence status, stage of the disease (chronic vs.
acute), mixed infections, different sources of infection (oocysts
vs. tissue cysts), HLA alleles, or age that could exert a strong
influence in the presence or absence of specific antibodies that
react to very few or a high number of epitopes in the parasite
antigens. Therefore, this reinforces the notion that the use of
single or few peptides for serotyping may lead to mistyping
and hence a large pool of polymorphic peptides from different
antigens should be used.
In addition to the low type-specificity of particular peptides,
previous work has shown that strongly immunoreactive peptides
may generate sufficient antibodies to non-polymorphic amino
acids within a polymorphic peptide, i.e., reactivity does not
necessarily predict strain serotype (Vaudaux et al., 2010). A
similar effect was evident herein, some peptides for which the
sequence was identical in types 1 and 2, 1 and 3, or 2 and 3
showed a much stronger reaction to one of them, but not both.
This may be accounted for by the presence of other polymorphic
immunogenic epitopes in the protein of certain strains that are
dominant and prevent other epitopes from reacting. This may
render the polymorphisms irrelevant in terms of strain reactivity.
For example, if region A is dominant in one strain, it is unlikely
that the reactivity against peptides on region B is high, regardless
of the polymorphic match with that particular strain. On the
contrary, it may be possible that the reactivity of other strains,
even when they do not correspond to that particular peptide
type, are stronger because region B is immunodominant in those
strains. Although it may seem counterproductive, this fact may
turn advantageous, as it can be used to identify certain strain
types by their distinctive behavior to specific peptides. This fact
may be particularly relevant in detecting non-archetypal strains:
even if a particular isolate shares the sequence with type 1, 2, or
3 strains, the reactivity may not be the same. A clear example of
this was the reactivity found in the human serum GUY-TER and
TOU-ALI. Despite sharing the same amino acid sequence in two
GRA6 and GRA7 peptides, the reactivity to these peptides was
different. This fact can be used as a marker for the distinction
between these two non-archetypal strains.
Similarly, a different amino acid sequence may not preclude
the samples from reacting against the archetypal version of a
specific peptide. Hence, by characterizing the unique reactivity
of a particular non-archetypal strain with peptides derived from
the type 1, 2, and 3 lineages, irrespective of the amino acid
sequence similarity, a characteristic signature of that strain can
be determined, which in turn can be used in the future for
its identification. Regardless, when the amino acid sequences of
GRA6 and GRA7 C-terminal peptides were compared between
the 64 strains available at ToxoDB, only 6 and 3 different
possibilities were, respectively, detected, which increased to 13
combinations when both peptides were compared together.
These different peptides have been previously shown to be
antigenically different (Vaudaux et al., 2010). As a consequence,
strains belonging to different haplogroups can have similar
reactivity to a peptide (e.g., type 2 has the same GRA6 C-
terminal sequence as MAS), but similarly all strains allocated
in the same haplogroup may not possess the same sequence.
This can be explained by the influence of recombination on the
global population structure of T. gondii (Lorenzi et al., 2016).
Indeed, many strains that are currently classified as belonging to
the same haplotype are genetically different, especially if they do
not belong to one of the clonal lineages. This further supports
the idea that it is the epitope, rather than the genetic type,
that determines the specificity of the peptide (Vaudaux et al.,
2010). As a matter of fact, atypical strains possessing different
epitopes at GRA6 and GRA7 generally induce antibodies that
either cross-react with non-polymorphic antigenic regions or do
not react.
On the other hand, our results highlight the importance that
single amino acid substitutions have on the peptide recognition.
The best example of this is the F/Y amino acid in the C-
terminal portion of GRA6. As pointed out previously, the
deletion of this amino acid eliminated all false positive results
(Kong et al., 2003). In the present work we further investigated
the importance of some amino acids compared to others by
designing different versions that were shorter or longer and that
varied at different levels in amino acid composition between
strains. Our results indicate and confirm that in the GRA6 C-
terminal, the GS/ER polymorphisms are not important, while
the EFDF/VFDY portion is much more relevant. Similarly,
the most important amino acid in a group of GRA7 peptides
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seems to be the K in position 229. This changes to E in all
the other strains that remain unreactive. These results clearly
indicate that the polymorphic site and length of peptide play a
significant role in serotyping, in accordance to previous studies
(Kong et al., 2003). When comparing the average length of
our set of peptides with other studies (Sousa et al., 2008;
Xiao et al., 2009; Maksimov et al., 2013), the shorter peptides
may improve the specificity, but affect sensitivity. However, in
longer peptides, the large number of conserved or invariant
amino acids that do not predict strain type often increase the
cross-reactivity and thus the false positive results (Sousa et al.,
2009). In addition, the alignment of the 64 strains available
in ToxoDB revealed a number of possible combinations of
amino acid sequences for different peptides. When we analyzed
the GRA6 and GRA7 C-terminal peptides, a total of 6 and 3
different combinations of alleles were, respectively, identified.
In theory, the same number of peptides could be designed to
identify the respective strains. However, as mentioned above,
certain polymorphisms seem to have a much stronger impact
on reactivity than others. Hence, in practice fewer than the
number of possible peptides will discriminate between strain
types. Future experiments should be conducted to determine
whether peptides from the different alleles are strain specific. This
could prove important in identifying atypical strains by using
archetypal-based peptides, even when the sequence is not exactly
the same.
Finally, although for logistic reasons we did not further
investigate all the peptides derived from proteins that were
antigenic in the arrays, these novel proteins possess potential
diagnostic properties that could be further tested in future
experiments. Notwithstanding, as a proof of concept, an ELISA
was performed with one of the most promising peptides
identified in our arrays: ESGEDREDAR. This novel peptide was
derived from GRA7 and shown to effectively discriminate type
3 infection in mice, rabbit and human serum samples with a
high specificity and sensitivity. By following this example, more
promising peptides could be tested with a larger collection of
gold standard samples by using an easier, more accessible to
all laboratories and affordable test such as ELISA. Nevertheless,
the need for a large pool of polymorphic peptides from
different loci is of paramount importance in order to define
all the different profiles from each strain and to compensate
for the high individual variability shown by both individual
peptides and samples. By increasing the number of peptides
that can be recognized by an individual serum and allow it
to be classified, the strain a person is infected with might be
unambiguously defined, as happens with current RFLP methods.
This, in turn, will allow large studies to be conducted that
can correlate the genotype of the infecting strains with disease
outcome to better understand the molecular epidemiology
of Toxoplasma.
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Supplemental File 3 | Strips from array 4 comparing individual peptides for each
serum sample from human patients. Strips from each array incubated with the
different samples were taken and put together as a comparison. Peptide numbers
are indicated above each group of strips. Patient identifications are indicated on
the left side of each strip. Pt and Dn stand for Patient and Donor, respectively.
Supplemental File 4 | Strips from array 5 comparing individual peptides for each
serum sample from human patients. Strips from each array incubated with the
different samples were taken and put together as a comparison. Peptide numbers
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